Stephen T Holgate

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8453799/publications.pdf

Version: 2024-02-01

81900 74163 7,075 78 39 75 citations g-index h-index papers 81 81 81 10619 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. Journal of Asthma, 2021, 58, 849-854.	1.7	8
2	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2021, 9, 196-206.	10.7	370
3	Anthony Barrington Kay 1939â€⊋020 Clinical and Experimental Allergy, 2021, 51, 206-208.	2.9	O
4	The clear and persistent impact of air pollution on chronic respiratory diseases: a call for interventions. European Respiratory Journal, 2021, 57, 2002981.	6.7	21
5	Accelerating the transition of clinical science to translational medicine. Clinical Science, 2021, 135, 2423-2428.	4.3	2
6	A method for the generation of large numbers of dendritic cells from CD34+ hematopoietic stem cells from cord blood. Journal of Immunological Methods, 2020, 477, 112703.	1.4	8
7	The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Journal of Physiology, 2020, 598, 3793-3801.	2.9	177
8	Overcoming fragmentation of health research in Europe: lessons from COVID-19. Lancet, The, 2020, 395, 1970-1971.	13.7	14
9	<i>Staphylococcus aureus</i> and its IgE-inducing enterotoxins in asthma: current knowledge. European Respiratory Journal, 2020, 55, 1901592.	6.7	71
10	Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet, The, 2020, 395, 1407-1409.	13.7	472
11	Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits. Journal of Clinical Medicine, 2020, 9, 1532.	2.4	50
12	Air pollution: The time has arrived for the medical profession to take ownership of the problem and act. Respirology, 2019, 24, 1138-1139.	2.3	3
13	The Future of Asthma Care. Clinics in Chest Medicine, 2019, 40, 227-241.	2.1	11
14	Letter from the UK (if we still exist after recent events!). Respirology, 2019, 24, 286-287.	2.3	0
15	The health effects of fine particulate air pollution. BMJ, The, 2019, 367, l6609.	6.0	49
16	Local action on outdoor air pollution to improve public health. International Journal of Public Health, 2018, 63, 557-565.	2.3	36
17	Physiotherapy breathing retraining for asthma: a randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 19-28.	10.7	97
18	Evaluating the long-term consequences of air pollution in early life: geographical correlations between coal consumption in 1951/1952 and current mortality in England and Wales. BMJ Open, 2018, 8, e018231.	1.9	12

#	Article	IF	CITATIONS
19	â€~Every breath we take: the lifelong impact of air pollution' – a call for action. Clinical Medicine, 2017, 17, 8-12.	1.9	81
20	The future of asthma research and development: a roadmap from the European Asthma Research and Innovation Partnership (EARIP). European Respiratory Journal, 2017, 49, 1602295.	6.7	18
21	The era of research collaborations: new models for working together. European Respiratory Journal, 2017, 49, 1601848.	6.7	11
22	A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults. Health Technology Assessment, 2017, 21, 1-162.	2.8	13
23	The ever-expanding ERS fellowship programmes: achievements over the past 3 years. European Respiratory Journal, 2016, 48, 595-599.	6.7	1
24	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	6.7	746
25	An inflammation-independent contraction mechanophenotype of airway smooth muscle in asthma. Journal of Allergy and Clinical Immunology, 2016, 138, 294-297.e4.	2.9	52
26	The European Respiratory Society evaluates its 2013–2018 strategic plan implementation. European Respiratory Journal, 2016, 47, 693-698.	6.7	3
27	Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life. JCI Insight, $2016,1,.$	5.0	31
28	The expanding role of immunopharmacology: <scp>IUPHAR</scp> Review 16. British Journal of Pharmacology, 2015, 172, 4217-4227.	5 . 4	23
29	A comment on "Scientometrics in a changing research landscape― EMBO Reports, 2015, 16, 261-261.	4.5	2
30	Human tissue models for a human disease: what are the barriers?. Thorax, 2015, 70, 695-697.	5 . 6	15
31	Drug development for airway diseases: looking forward. Nature Reviews Drug Discovery, 2015, 14, 367-368.	46.4	18
32	Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization. World Allergy Organization Journal, 2015, 8, 25.	3.5	328
33	Asthma in the elderly: what we know and what we have yet to know. World Allergy Organization Journal, 2014, 7, 8.	3.5	105
34	Omalizumab in Asthma: An Update on Recent Developments. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 525-536.e1.	3.8	179
35	New strategies with anti-IgE in allergic diseases. World Allergy Organization Journal, 2014, 7, 17.	3.5	48
36	Asthma genetics and personalised medicine. Lancet Respiratory Medicine, the, 2014, 2, 405-415.	10.7	91

#	Article	IF	CITATIONS
37	Stratified approaches to the treatment of asthma. British Journal of Clinical Pharmacology, 2013, 76, 277-291.	2.4	41
38	Discovery of new treatments in the context of delivering personalized medicine. Personalized Medicine, 2012, 9, 101-104.	1.5	1
39	Chronic fatigue syndrome: understanding a complex illness. Nature Reviews Neuroscience, 2011, 12, 539-544.	10.2	86
40	Perspective: A human touch. Nature, 2011, 479, S22-S22.	27.8	4
41	Asthma: a simple concept but in reality a complex disease. European Journal of Clinical Investigation, 2011, 41, 1339-1352.	3.4	61
42	The sentinel role of the airway epithelium in asthma pathogenesis. Immunological Reviews, 2011, 242, 205-219.	6.0	338
43	A new look at the pathogenesis of asthma. Clinical Science, 2010, 118, 439-450.	4.3	177
44	A Brief History of Asthma and Its Mechanisms to Modern Concepts of Disease Pathogenesis. Allergy, Asthma and Immunology Research, 2010, 2, 165.	2.9	53
45	Exposure, Uptake, Distribution and Toxicity of Nanomaterials in Humans. Journal of Biomedical Nanotechnology, 2010, 6, 1-19.	1.1	97
46	A look at the pathogenesis of asthma: the need for a change in direction. Discovery Medicine, 2010, 9, 439-47.	0.5	41
47	The Role of the Airway Epithelium and its Interaction with Environmental Factors in Asthma Pathogenesis. Proceedings of the American Thoracic Society, 2009, 6, 655-659.	3.5	169
48	Rethinking the Pathogenesis of Asthma. Immunity, 2009, 31, 362-367.	14.3	65
49	The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respiratory Medicine, 2009, 103, 1098-1113.	2.9	109
50	Novel targets of therapy in asthma. Current Opinion in Pulmonary Medicine, 2009, 15, 63-71.	2.6	44
51	The Airway Epithelium is Central to the Pathogenesis of Asthma. Allergology International, 2008, 57, 1-10.	3.3	274
52	The epithelium takes centre stage in asthma and atopic dermatitis. Trends in Immunology, 2007, 28, 248-251.	6.8	175
53	Epithelium dysfunction in asthma. Journal of Allergy and Clinical Immunology, 2007, 120, 1233-1244.	2.9	423
54	Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. Journal of Allergy and Clinical Immunology, 2006, 117, 496-506.	2.9	133

#	Article	lF	Citations
55	ADAM33: a newly identified protease involved in airway remodelling. Pulmonary Pharmacology and Therapeutics, 2006, 19, 3-11.	2.6	39
56	The Mouse Trap. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1173-1176.	5.6	132
57	The Quintiles Prize Lecture 2004: The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. British Journal of Pharmacology, 2005, 145, 1009-1015.	5.4	91
58	ADAM33: A Newly Identified Gene in the Pathogenesis of Asthma. Immunology and Allergy Clinics of North America, 2005, 25, 655-668.	1.9	12
59	A treatment for allergic rhinitis:a view on the role of levocetirizine. Current Medical Research and Opinion, 2005, 21, 1099-1106.	1.9	12
60	Epithelial-Mesenchymal Communication in the Pathogenesis of Chronic Asthma. Proceedings of the American Thoracic Society, 2004, 1, 93-98.	3. 5	195
61	ADAM 33 and Its Association With Airway Remodeling and Hyperresponsiveness in Asthma. Clinical Reviews in Allergy and Immunology, 2004, 27, 023-034.	6.5	24
62	Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine, 2004, 28, 152-157.	3.2	58
63	The epidemic of asthma and allergy. Journal of the Royal Society of Medicine, 2004, 97, 103-110.	2.0	37
64	New targets for allergic rhinitis â€" a disease of civilization. Nature Reviews Drug Discovery, 2003, 2, 903-915.	46.4	59
65	Health effects of acute exposure to air pollution. Part I: Healthy and asthmatic subjects exposed to diesel exhaust. Research Report (health Effects Institute), 2003, , 1-30; discussion 51-67.	1.6	33
66	Health effects of acute exposure to air pollution. Part II: Healthy subjects exposed to concentrated ambient particles. Research Report (health Effects Institute), 2003, , 31-50; discussion 51-67.	1.6	12
67	The Contribution of Interleukin (IL)-4 and IL-13 to the Epithelial–Mesenchymal Trophic Unit in Asthma. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 385-391.	2.9	260
68	Immunohistochemical analysis of the activation of NFâ€PB and expression of associated cytokines and adhesion molecules in human models of allergic inflammation. Journal of Pathology, 1999, 189, 265-272.	4.5	35
69	Clonally related IgE and IgG4 transcripts in blood lymphocytes of patients with asthma reveal differing patterns of somatic mutation. European Journal of Immunology, 1998, 28, 3354-3361.	2.9	29
70	Human mast cells express stem cell factor. , 1998, 186, 59-66.		104
71	Pattern of usage and somatic hypermutation in the VH5 gene segments of a patient with asthma: Implications for IgE. European Journal of Immunology, 1997, 27, 162-170.	2.9	44
72	Asthma: A Dynamic Disease of Inflammation and Repair. Novartis Foundation Symposium, 1997, 206, 5-34.	1.1	28

STEPHEN T HOLGATE

#	Article	lF	CITATION
73	The Mast Cell as a Source of Cytokines in Asthma. Annals of the New York Academy of Sciences, 1996, 796, 272-281.	3.8	41
74	Immunogenetics of human IgE. Human Antibodies, 1996, 7, 157-166.	1.5	10
75	Release of Mast-Cell-derived Mediators after Endobronchial Adenosine Challenge in Asthma. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 624-629.	5.6	153
76	Clinical Pharmacology of Asthma. Drugs, 1993, 46, 847-862.	10.9	14
77	Inflammatory processes and bronchial hyperresponsiveness. Clinical and Experimental Allergy, 1991, 21, 30-36.	2.9	32
78	Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. Journal of Pathology, 1990, 162, 119-126.	4.5	164